Sofie Bjärtun specialises in capital markets, public M&A, general corporate matters and corporate governance. She has broad experience from takeovers, IPOs, capital raisings and other capital markets transactions. Sofie also advises boards and management teams on corporate governance, disclosure and securities law matters on a continuous basis.
Sofie Bjärtun is ranked as a Rising star partner in IFLR 1000 2023
Vinge has advised EQT IX (”EQT”) in connection with the sale of shares in Beijer Ref AB (publ) throu…
In total, 7.6 million shares were placed at a price of SEK 64 per share, corresponding to a total va…
EQT Infrastructure VI, through its indirectly owned subsidiary Otello BidCo AB, announces a recommen…
In total, 7.7 million shares were placed at a price of SEK 57.50 per share, corresponding to a total…
In total, 8.4 million shares were placed at a price of SEK 43.50 per share, corresponding to a total…
Vinge has advised EQT IX (”EQT”) in connection with the sale of shares in Beijer Ref AB (publ) throu…
FCG Holding Sverige AB has announced a recommended public offer in cash to the shareholders of Trans…
EQT AB (publ) has completed the issuance of a EUR 750,000,000 sustainability-linked bond maturing in…
Vinge has advised EQT in connection with the combination with Baring Private Equity Asia, a leading…
Vinge acts as lead advisor to EQT AB in connection with its acquisition of Life Sciences Partners, a…
The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EU…
Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm…
The board of directors of Medicover has, on the basis of an authorisation granted from the annual ge…
Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasd…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately…
Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockh…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge advises Finanzero in connection with the company's capital raising of approximately SEK 100 mi…
In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total v…
Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the l…
Vinge advises ABG Sundal Collier, Skandinaviska Enskilda Banken and Swedbank who are acting as Joint…
The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the…
Vinge advises Finanzero in connection with the company's capital raising of approximately SEK 30 mil…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised Pandox Aktiebolag (publ) with certain financing and capital markets related questi…
Vinge assisted EQT V Limited (”EQT”) in connection with the sale of shares in AcadeMedia AB (publ) (…
Vinge advises DGC One AB (publ) (“DGC”) in connection with EQT’s acquisition of 85.2 percent of the…
Vinge advises Medicover AB (publ) (“Medicover”) and its main shareholder Celox Holding AB (“Celox”),…
Advokat Sofie Bjärtun, advokat Rikard Lindahl, advokat Malin Malm Waerme and advokat Daniel Wendelss…
